240 related articles for article (PubMed ID: 6633564)
41. Resealed fiber segments for the study of the pathophysiology of human skeletal muscle.
Lehmann-Horn F; Iaizzo PA
Muscle Nerve; 1990 Mar; 13(3):222-31. PubMed ID: 2320044
[TBL] [Abstract][Full Text] [Related]
42. Ca2+ sensitivity and caffeine-induced changes in skinned cardiac muscle fibers of the carp, Cyprinus carpio.
Chugun A; Temma K; Kondo H; Kurebayashi N
J Comp Physiol B; 1996; 166(7):412-7. PubMed ID: 8956502
[TBL] [Abstract][Full Text] [Related]
43. Phosphorylase ratio and susceptibility to malignant hyperthermia.
Traynor CA; Van Dyke RA; Gronert GA
Anesth Analg; 1983 Mar; 62(3):324-6. PubMed ID: 6299136
[TBL] [Abstract][Full Text] [Related]
44. Is theophylline, aminophylline, or caffeine (methylxanthines) contraindicated in malignant hyperthermia susceptible patients?
Flewellen EH; Nelson TE
Anesth Analg; 1983 Jan; 62(1):115-8. PubMed ID: 6849503
[No Abstract] [Full Text] [Related]
45. The Israeli Diagnostic Center for Malignant Hyperthermia: 7-years' accumulated experience.
Glauber V; Ben Abraham R; Zweig A; Perel A
Isr J Med Sci; 1997 Oct; 33(10):643-7. PubMed ID: 9397136
[TBL] [Abstract][Full Text] [Related]
46. Is resting membrane potential a possible indicator of viability of muscle bundles used in the in vitro caffeine contracture test?
Adnet PJ; Krivosic-Horber RM; Adamantidis MM; Haudecoeur G; Reyford HG; Dupuis BA
Anesth Analg; 1992 Jan; 74(1):105-11. PubMed ID: 1734769
[TBL] [Abstract][Full Text] [Related]
47. Central core disease and malignant hyperthermia syndrome.
Frank JP; Harati Y; Butler IJ; Nelson TE; Scott CI
Ann Neurol; 1980 Jan; 7(1):11-7. PubMed ID: 7362206
[TBL] [Abstract][Full Text] [Related]
48. Malignant hyperthermia: a disease of specific myofiber type?
Nelson TE; Schochet SS
Can Anaesth Soc J; 1982 Mar; 29(2):163-7. PubMed ID: 7066741
[TBL] [Abstract][Full Text] [Related]
49. Comparative analysis of in vitro contracture tests with ryanodine and a combination of ryanodine with either halothane or caffeine: a comparative investigation in malignant hyperthermia.
Bendahan D; Guis S; Monnier N; Kozak-Ribbens G; Lunardi J; Ghattas B; Mattei JP; Cozzone PJ
Acta Anaesthesiol Scand; 2004 Sep; 48(8):1019-27. PubMed ID: 15315621
[TBL] [Abstract][Full Text] [Related]
50. [Biology of malignant hyperthermia: a disease of the calcium channels of the skeletal muscle].
Monnier N; Lunardi J
Ann Biol Clin (Paris); 2000; 58(2):147-56. PubMed ID: 10760701
[TBL] [Abstract][Full Text] [Related]
51. Asymptomatic or minimally symptomatic hyperCKemia: histopathologic correlates.
Dabby R; Sadeh M; Herman O; Berger E; Watemberg N; Hayek S; Jossiphov J; Nevo Y
Isr Med Assoc J; 2006 Feb; 8(2):110-3. PubMed ID: 16544734
[TBL] [Abstract][Full Text] [Related]
52. [Effects of amrinone on the Ca(2+)-related functions of skinned skeletal muscle fibers of guinea pigs].
Sasaki J
Masui; 1999 Jan; 48(1):18-26. PubMed ID: 10036884
[TBL] [Abstract][Full Text] [Related]
53. In vitro contractile responses and contracture testing of skeletal muscle from Quarter Horses with exertional rhabdomyolysis.
Lentz LR; Valberg SJ; Mickelson JR; Gallant EM
Am J Vet Res; 1999 Jun; 60(6):684-8. PubMed ID: 10376892
[TBL] [Abstract][Full Text] [Related]
54. Site of the muscle cell abnormality in swine susceptible to malignant hyperpyrexia.
Okumura F; Crocker BD; Denborough MA
Br J Anaesth; 1980 Apr; 52(4):377-83. PubMed ID: 7378237
[TBL] [Abstract][Full Text] [Related]
55. Malignant hyperthermia.
Blanck TJ; Gruener RP
Biochem Pharmacol; 1983 Aug; 32(15):2287-9. PubMed ID: 6349642
[No Abstract] [Full Text] [Related]
56. Malignant hyperthermia: relation to other diseases.
Mortier W
Acta Anaesthesiol Belg; 1990; 41(2):119-26. PubMed ID: 2164741
[No Abstract] [Full Text] [Related]
57. Electrophysiologic properties of intercostal muscle fibers in human neuromuscular diseases.
Gruener R; Stern LZ; Markovitz D; Gerdes C
Muscle Nerve; 1979; 2(3):165-72. PubMed ID: 503103
[TBL] [Abstract][Full Text] [Related]
58. [Malignant hyperthermia].
Campos Suárez JM; Escolano Villén F; Catalá Puigbó E; Villar Landeira JM
Rev Esp Anestesiol Reanim; 1985; 32(4):169-78. PubMed ID: 3901157
[No Abstract] [Full Text] [Related]
59. Dental treatment for a patient with Duchenne muscular dystrophy and malignant hyperthermia.
Cherny I; Lopez JI; Schuman NJ
Gen Dent; 1986; 34(4):299-300. PubMed ID: 2943633
[No Abstract] [Full Text] [Related]
60. A pharmacological in vitro model of malignant hyperpyrexia.
Harrison GG
S Afr Med J; 1973 May; 47(18):774-6. PubMed ID: 4267976
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
